Bourgeon Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Bourgeon Capital Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-103	Closed	-$1.47K	–	347
2023 Q4	$1.47K	Buy	103 +24	+30%	+$341	﹤0.01%	311
2023 Q3	$1.22K	Buy	+79	New	+$1.22K	﹤0.01%	299
2020 Q4	–	Sell	-97	Closed	-$2K	–	322
2020 Q3	$2K	Buy	+97	New	+$1.77K	﹤0.01%	260

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bourgeon Capital Management's TAK Position: Q1 2024 in Review

Bourgeon Capital Management sold out of Takeda Pharmaceutical (TAK) in Q1 2024, closing a stake of 103 shares — an estimated $1.47K sold.

Bourgeon Capital Management first reported a position in TAK in Q3 2020 and held it in 3 quarters. The position peaked at $2K in Q3 2020. 313 funds tracked by Wall St. Rank hold TAK as of Q1 2024.

Bourgeon Capital Management reported no remaining Takeda Pharmaceutical position as of Q1 2024 after selling out during the quarter.
Bourgeon Capital Management sold 103 Takeda Pharmaceutical shares in Q1 2024, an estimated $1.47K.
Bourgeon Capital Management first reported a position in Takeda Pharmaceutical in Q3 2020 and held it in 3 quarters.
Bourgeon Capital Management's Takeda Pharmaceutical position peaked at $2K in Q3 2020.
313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2024.

Based on Bourgeon Capital Management's 13F filing for Q1 2024, filed 19 Apr 2024.